参附注射液辅助治疗中晚期恶性肿瘤对提高生活质量的临床研究

目的：进一步提高中晚期恶性肿瘤患者的生活质量。方法：从2001年1月－2002年6月120例中晚期恶性肿瘤患者按组间均衡设计分为单纯放疗组（对照组）和放射联合参附注射液治疗组（试验组），每组60例。评估二组病人放疗结束后的生活质量的改善及局控率。分析放疗前后CD3^ ,CD4^ ,CD4^ /CD8^ 的变化。结果：治疗组局控率（CR）为78．3％，而对照组为73．8％，无显著性差异（P＞0．05）；放疗后对照组CD3^ ,CD4^ ,CD4^ /CD8^ 降低，CD8^ 增高，放疗前后对比有显著性差异（P＜0．01），而治疗组放疗前后无显著差异；治疗组头晕、乏力缓解率为81．5％，对照组为44．8％，有显著性差异（P＜0．01），治疗组骨髓抑制较对照组明显减轻。结论：在中晚期恶性肿瘤放疗过程中联合使用参附注射液能增强肿瘤患者的免疫功能，提高生活质量，且副作用轻，但不能提高局控率。

A CLINICAL STUDY OF SF INJECTION AS AN ADJUVANT THERAPY FOR PATIENTS WITH MIDDLE OR ADVANCED CARCINOMA IN LIFE QUALITY

Objective:To further improve the life quality of patients with middle or advanced carcinoma. Methods:From 2001 to 2002,120 patients with middle or advanced carcinoma were divided equally into two groups: control group(radiother apyalone), test group (combination of radiotherapy with SF injection), we assessed the life quality of patients, evaluated the local control rate of the two groups by the end of radiotherapy, analyzed the variation of CD3 +,CD4 +, CD4 +/CD8 + before radiotherapy and after radiotherapy respectively. Results:The local control rate of test group(CR) was 78.3%, while it was 73.3% in control group, there were no obvious difference(P>0.05).In the end of radiotherapy, CD3 +,CD4 +, CD4 +/CD8 + descended, CD8 + ascended (P<0.01)in control group and these changed slightly in test group.The response(dizziness-alleviating) rate were 81.5% in test group and 44.8% in control group, The difference between these two groups was significant (P < 0.01). After starting radiotherapy, WBC was obviously decreased in control group, while the decrease was slight in test group.Conclusions:The combination of radiotherapy with SF injection may increase immunity function of patients and improve the patients's life quality, but can not promote the vanishing of carcinoma.